Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 559-570 , July 2007

Radiosynthesis and biological evaluation of an 18F-labeled derivative of the novel pyrazolopyrimidine sedative–hypnotic agent indiplon

  • Alexander Hoepping

      Affiliations

    • ABX Advanced Biochemical Compounds GmbH, 01454 Radeberg, Germany
    • A. Hoepping, M. Scheunemann, S. Fischer and W. Deuther-Conrad contributed equally in this study.
    • ,
  • Matthias Scheunemann

      Affiliations

    • Institute of Interdisciplinary Isotope Research, 04318 Leipzig, Germany
    • A. Hoepping, M. Scheunemann, S. Fischer and W. Deuther-Conrad contributed equally in this study.
    • ,
  • Steffen Fischer

      Affiliations

    • Institute of Interdisciplinary Isotope Research, 04318 Leipzig, Germany
    • A. Hoepping, M. Scheunemann, S. Fischer and W. Deuther-Conrad contributed equally in this study.
    • ,
  • Winnie Deuther-Conrad

      Affiliations

    • Institute of Interdisciplinary Isotope Research, 04318 Leipzig, Germany
    • A. Hoepping, M. Scheunemann, S. Fischer and W. Deuther-Conrad contributed equally in this study.
    • ,
  • Achim Hiller

      Affiliations

    • Institute of Interdisciplinary Isotope Research, 04318 Leipzig, Germany
    • ,
  • Florian Wegner

      Affiliations

    • Department of Neurology, University of Leipzig, 04103 Leipzig, Germany
    • ,
  • Michael Diekers

      Affiliations

    • ABX Advanced Biochemical Compounds GmbH, 01454 Radeberg, Germany
    • ,
  • Jörg Steinbach

      Affiliations

    • Institute of Interdisciplinary Isotope Research, 04318 Leipzig, Germany
    • ,
  • Peter Brust

      Affiliations

    • Institute of Interdisciplinary Isotope Research, 04318 Leipzig, Germany
    • Corresponding Author InformationCorresponding author. Institut für Interdisziplinäre Isotopenforschung, D-04318 Leipzig, Germany. Tel.: +49 0341 235 4013; fax:+49 0341 235 2731.

Received 5 February 2007 ,Revised 19 March 2007 ,Accepted 27 March 2007.

References 

  1. Darlison MG, Pahal I, Thode C. Consequences of the evolution of the GABAA receptor gene family. Cell Mol Neurobiol. 2005;25:607–624
  2. Johnston GA. GABAA receptor channel pharmacology. Curr Pharm Des. 2005;11:1867–1885
  3. Steriade M. Sleep, epilepsy and thalamic reticular inhibitory neurons. Trends Neurosci. 2005;28:317–324
  4. Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci. 2005;30:167–175
  5. Krystal JH, Staley J, Mason G, Petrakis IL, Kaufman J, Harris RA, et al. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry. 2006;63:957–968
  6. Rout UK. Alcohol, GABA receptors, and neurodevelopmentaldisorders. Int Rev Neurobiol. 2005;71:217–237
  7. Möhler H, Crestani F, Rudolph U. GABAA-receptor subtypes: a new pharmacology. Curr Opin Pharmacol. 2001;1:22–25
  8. Tsang SY, Xue H. Development of effective therapeutics targeting the GABAA receptor: naturally occurring alternatives. Curr Pharm Des. 2004;10:1035–1044
  9. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat Rev Neurosci. 2005;6:215–229
  10. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci. 1992;12:1040–1062
  11. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adin J. Ion channels and epilepsy. Curr Pharm Des. 2005;11:1975–2003
  12. Maziere M, Hantraye P, Prenant C, Sastre J, Comar D. Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot. 1984;35:973–976
  13. Goethals I, Van De Wiele C, Boon P, Dierckx R. Is central benzodiazepine receptor imaging useful for the identification of epileptogenic foci in localization-related epilepsies?. Eur J Nucl Med Mol Imaging. 2003;30:325–328
  14. Bartenstein P. PET in neuroscience: dopaminergic. GABA/benzodiazepine, and opiate system. Nuklearmedizin. 2004;43:33–42
  15. Katsifis A, Kassiou M. Development of radioligands for in vivo imaging of GABAA-benzodiazepine receptors. Mini Rev Med Chem. 2004;4:909–921
  16. Wadsak W, Mitterhäuser M, Mien LK, Togel S, Keppler B, Dudczak R, et al. Radiosynthesis of 3-(2′-[18F]fluoro)-flumazenil ([18F]FFMZ). J Label Compd Radiopharm. 2003;46:1229–1240
  17. Yoon YH, Jeong JM, Kim HW, Hong SH, Lee YS, Kil HS, et al. Novel one-pot one-step synthesis of 2′-[18F]fluoroflumazenil (FFMZ) for benzodiazepine receptor imaging. Nucl Med Biol. 2003;30:521–527
  18. Moerlein SM, Perlmutter JS. Binding of 5-(2′-[18F]fluoroethyl)flumazenil to central benzodiazepine receptors measured in living baboon by positron emission tomography. Eur J Pharmacol. 1992;218:109–115
  19. Gründer G, Siessmeier T, Lange-Asschenfeldt C, Vernaleken I, Buchholz HG, Stoeter P, et al. [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur J Nucl Med. 2001;28:1463–1470
  20. Ryzhikov NN, Seneca N, Krasikova RN, Gomzina NA, Shchukin E, Fedorova OS, et al. Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol. 2005;32:109–116
  21. Chang YS, Jeong JM, Yoon YH, Kang WJ, Lee SJ, Lee DS, et al. Biological properties of 2′-[18F]fluoroflumazenil for central benzodiazepine receptor imaging. Nucl Med Biol. 2005;32:263–268
  22. Mitterhäuser M, Wadsak W, Wabnegger L, Mien LK, Tögel S, Langer O, et al. Biological evaluation of 2′-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nucl Med Biol. 2004;31:291–295
  23. Sullivan SK, Petroski RE, Verge G, Gross RS, Foster AC, Grigoriadis DE. Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor. J Pharmacol Exp Ther. 2004;311:537–546
  24. Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, et al. Indiplon is a high-affinity positive allosteric modulator with selectivity for α1 subunit containing GABAA receptors. J Pharmacol Exp Ther. 2006;317:369–377
  25. Thiele WJ, O'Donnell PB. Polymorphs of N-methyl-N-(3-(3-[2-thienylcarbonyl]-pyrazol-[1,5-a]-pyrimidin-7-yl) phenyl)acetamide and compositions and methods related thereto. Neurocrine Biosciences, Inc., US Patent 6,384,221, 2002.
  26. Briard E, Pike VW. Substitution–reduction: an alternative process for the [18F]N-(2-fluoroethylation) of anilines. J Label Compd Radiopharm. 2004;47:217–232
  27. Olsen RW, McCabe RT, Wamsley JK. GABAA receptor subtypes: autoradiographic comparison of GABA, benzodiazepine, and convulsant binding sites in the rat central nervous system. J Chem Neuroanat. 1990;3:59–76
  28. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–3108
  29. CambridgeSoft Corporation. CS ChemDraw Ultra chemical structure drawing standard. www.camsoft.com, 1998.
  30. Seiler P. Interconversion of lipophilicities from hydrocarbon–water systems into octanol–water system. Eur J Med Chem. 1974;9:473–479
  31. Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem. 1988;31:656–671
  32. Chavoix C, Hantraye P, Brouillet E, Guibert B, Fukuda H, De la Sayette V, et al. Status epilepticus induced by pentylenetetrazole modulates in vivo [11C]Ro 15-1788 binding to benzodiazepine receptors. Effects of ligands acting at the supramolecular receptor complex. Eur J Pharmacol. 1988;146:207–214
  33. Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L. In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet. 1988;2:863–866
  34. Duncan JS. Brain imaging in idiopathic generalized epilepsies. Epilepsia. 2005;46(Suppl 9):108–111
  35. Holthoff VA, Koeppe RA, Frey KA, Penney JB, Markel DS, Kuhl DE, et al. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. Ann Neurol. 1993;34:76–81
  36. Künig G, Leenders KL, Sanchez-Pernaute R, Antonini A, Vontobel P, Verhagen A, et al. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. Ann Neurol. 2000;47:644–648
  37. Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol. 1995;52:314–317
  38. Sedvall G, Pauli S, Karlsson P, Farde L, Nordström AL, Nyberg S, et al. PET imaging of neuroreceptors in schizophrenia. Eur Neuropsychopharmacol. 1995;5:25–30
  39. Abadie P, Boulenger JP, Benali K, Barre L, Zarifian E, Baron JC. Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study in process citation. Eur J Neurosci. 1999;11:1470–1478
  40. Matsunaga T, Tsukada H, Nishiyama S, Sekine Y, Kakiuchi T, Iyo M, et al. Yohimbine increases the binding potential for [11C]flumazenil in the monkey brain. J Neural Transm. 2001;108:1375–1382
  41. Noda A, Takamatsu H, Murakami Y, Yajima K, Tatsumi M, Ichise R, et al. Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys. J Nucl Med. 2003;44:105–108
  42. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABAA-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715–720
  43. Duncan JS. Positron emission tomography receptor studies. In:  Delgado-Escueta AV,  Wilson WA,  Olsen RW,  Porter RJ editor. Jasper's basic mechanisms of the epilepsies. Third edition: advances in neurology. vol 79:Philadelphia: Lippincott Williams & Wilkins; 1999;p. 893–899
  44. Raymond AA, Fish DR, Sisodiya SM, Alsanjari N, Stevens JM, Shorvon SD. Abnormalities of gyration, heterotopias, tuberous sclerosis, focal cortical dysplasia, microdysgenesis, dysembryoplastic neuroepithelial tumour and dysgenesis of the archicortex in epilepsy. Clinical, EEG and neuroimaging features in 100 adult patients. Brain. 1995;118:629–660
  45. Laurie DJ, Wisden W, Seeburg PH. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J Neurosci. 1992;12:4151–4172
  46. Kanaumi T, Takashima S, Iwasaki H, Mitsudome A, Hirose S. Developmental changes in the expression of GABAA receptor alpha 1 and gamma 2 subunits in human temporal lobe, hippocampus and basal ganglia: an implication for consideration on age-related epilepsy. Epilepsy Res. 2006;71:47–53
  47. Raol YH, Zhang G, Lund IV, Porter BE, Maronski MA, Brooks-Kayal AR. Increased GABAA-receptor α1-subunit expression in hippocampal dentate gyrus after early-life status epilepticus. Epilepsia. 2006;47:1665–1673
  48. Raol YH, Lund IV, Bandyopadhyay S, Zhang G, Roberts DS, Wolfe JH, et al. Enhancing GABAA receptor α1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci. 2006;26:11342–11346
  49. Kim EY, Shin KM, Jang S, Oh S. Changes of [3H]muscimol, [3H]flunitrazepam and [3H]MK-801 binding in rat brain by prolonged ventricular infusion of 7-nitroindazole. Neurochem Res. 2004;29:2221–2229
  50. Dubiela FP, de Oliveira MG, Moreira KD, Nobrega JN, Tufik S, Hipolide DC. Learning deficits induced by sleep deprivation and recovery are not associated with altered [3H]muscimol and [3H]flunitrazepam binding. Brain Res. 2005;1037:157–163
  51. Armstrong BD, Noguchi KK. The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in vitro autoradiographic study in rats. Neurotoxicology. 2004;25:905–914
  52. Chugani DC, Muzik O, Juhasz C, Janisse JJ, Ager J, Chugani HT. Postnatal maturation of human GABAA receptors measured with positron emission tomography. Ann Neurol. 2001;49:618–626
  53. Lucignani G, Panzacchi A, Bosio L, Moresco RM, Ravasi L, Coppa I, et al. GABAA receptor abnormalities in Prader–Willi syndrome assessed with positron emission tomography and [11C]flumazenil. Neuroimage. 2004;22:22–28
  54. Ihara M, Tomimoto H, Ishizu K, Mukai T, Yoshida H, Sawamoto N, et al. Decrease in cortical benzodiazepine receptors in symptomatic patients with leukoaraiosis: a positron emission tomography study. Stroke. 2004;35:942–947
  55. Lingford-Hughes AR, Wilson SJ, Cunningham VJ, Feeney A, Stevenson B, Brooks DJ, et al. GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. Psychopharmacology (Berl). 2005;180:595–606
  56. McLeod M, Pralong D, Copolov D, Dean B. The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H]flumazenil and zolpidem. Mol Brain Res. 2002;104:203–209
  57. Suehiro M, Scheffel U, Dannals RF, Ravert HT, Ricaurte GA, Wagner HN. A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z. J Nucl Med. 1993;34:121–127
  58. Brust P, Hesse S, Müller U, Szabo Z. Neuroimaging of the serotonin transporter — possibilities and pitfalls. Curr Psychiat Rev. 2006;2:111–149
  59. Dumont F, Waterhouse RN, Montoya JA, Mattner F, Katsifis A, Kegeles LS, et al. Synthesis and in vivo evaluation of [11C]zolpidem, an imidazopyridine with agonist properties at central benzodiazepine receptors. Nucl Med Biol. 2003;30:435–439
  60. Foster AC, Pelleymounter MA, Cullen MJ, Lewis D, Joppa M, Chen TK, et al. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative–hypnotic. J Pharmacol Exp Ther. 2004;311:547–559
  61. Neubauer DN. Indiplon: the development of a new hypnotic. Expert Opin Investig Drugs. 2005;14:1269–1276
  62. Dienel GA, Popp D, Drew PD, Ball K, Krisht A, Cruz NF. Preferential labeling of glial and meningial brain tumors with [2-14C]acetate. J Nucl Med. 2001;42:1243–1250
  63. Lear JL, Ackermann RF. Evaluation of radiolabeled acetate and fluoroacetate as potential tracers of cerebral oxidative metabolism. Metab Brain Dis. 1990;5:45–56

PII: S0969-8051(07)00093-5

doi: 10.1016/j.nucmedbio.2007.03.011

Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 559-570 , July 2007

Article Tools

* Image Usage & Resolution